Antifungal Class:


Antifungal Spectrum:

Opportunisitic yeasts:  Candida albicans, Candida tropcialis, Cryptococcus neoformans, Candida glabrata (variable activity), Candida krusei (variable activity)

Opportunistic hyaline moulds: Aspergillus spp., Scedosporium spp. (variable activity)

Dimorphic moulds:  Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Parracoccidioides brasiliensis, Sporothrix schenkii, Penicillium marneffei

Zygomycetes:  Entomophthorales (variable activity)

Dematiaceous moulds:  variable activity

Mechanism of Action:

Inhibits fungal cytochrome P450 3A dependent enzyme, decreases ergosterol synthesis and inhibits cell membrane formation.


AUC:MIC of the pathogen strongly correlates with efficacy in Candida species. This may vary in differing species.


Tmax: 1.5-4 hours; Cmax:10 mcg/ml; Vd: 10.7 L/Kg; Total Clearance: 3.8 ml/min/Kg; Table 2

Adverse Effects:

Gastrointestinal: nausea, vomiting, abdominal pain

Cardiovascular System: edema, hypertension

Dermatologic: skin rashes, pruritus

Central Nervous System: headache, dizziness, fatigue

Endocrine & metabolic: hypertrigliceridemia, decreased libido, hypokalemia

Hepatic: abnormal LFTs, hepatitis

Renal:  albuminuria


Capsule:  100 mg

Injection, solution:  10 mg/mL (25 mL)

Solution, oral:  100mg/10mL (150 mL)


Oral:  100-400 mg/day (capsules);  2.5 mg/kg (HP-beta-CD solution)

Life-threatening infections - loading dose: 600 to 800 mg/day for 3-5 days

                                              maintenance dose:  400 to 600 mg/day

Intravenous:  200 mg twice a day for 2 days, followed by 200 mg once daily for a maximum of 14 days altogether

Children < 18 years:

Oral:  5 to 8 mg/kg/d with a loading dose of 4 mg/kg three times a day for the first three days (capsules);  2.5 mg/kg twice a day (HP-beta-CD solution)

Disease state based dosing:

Renal failure:  Oral itraconazole does not need adjusted; intravenous itraconazole is contraindicated in patients with a creatinine clearance less than 30 mL/min.

Hepatic failure:  The elimination half-life can be prolonged, and additional hepatic toxicity or possible drug interactions should be carefully monitored.


Contraindications: Concurrent administration with astemizole, cisapride, dofetilide, ergot derivatives, lovastatin, midazolam, pimozide, quinide, simvastatin

Precautions: Rare cases of serious cardiovascular events, including death, ventricular tachycardia, and torsades with concominant cisapride administration.

Drug Interactions:

Table 4

Itraconazole is a potent inhibitor of the cytochrome P450 3A4 isoenzyme system.  Caution should be exercised and monitoring is suggested when concomitantly administering itraconazole with drugs that have narrow therapeutic windows and are substrates of the CYP3A4 substrates.


Category C: Risk unknown. Human studies inadequate.

Monitoring Requirements:

Plasma levels:  0.5 mcg/mL at trough for invasive fungal infections

Brand names/Manufacturer: